TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12579025
Drug: One-step povidone-iodine
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One-step povidone-iodine topical gel
Study: 16966616
Drug: 0.5% timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% timolol maleate twice daily
Study: 1874212
Drug: Propofol 20‐200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 20‐200 mg h‐1
Study: 24104763
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of propofol and alfentanil
Study: 6115732
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg propranolol
Study: 20096821
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) plus metformin
Study: 31677181
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus metformin (Plac/Met)
Study: 31358588
Drug: Artemisinin-based combination
Normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisinin-based combination therapy (ACT); specific details on dosage and duration not provided.
Study: 26209863
Drug: ENG implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: ENG implant inserted within 48 h after delivery
Study: 1945579
Drug: PRP-T mixed
Normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP-T mixed with DTP vaccine in a single syringe (Group A)
Study: 7021072
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg soluble aspirin
Study: 30062716
Drug: Paricalcitol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paricalcitol (2 μg/day for 24 weeks)
Study: 22978098
Drug: Yupei Qisun
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yupei Qisun Sequential Method (YQSM) combined with IVF/ICSI
Study: 20139233
Drug: Testosterone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone (5 mg/d) in elderly men
Study: 20139233
Drug: DHEA (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA (50 mg/d) in elderly women
Study: 21278555
Drug: Extended release
Normalized name: Tylenol Extended Release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended release epidural morphine (DepoDur)
Study: 19038468
Drug: Concomitant and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant and adjuvant short-term hormonal treatments with curative radiotherapy
Study: 1674105
Drug: Ursodiol (13
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodiol (13 to 15 mg per kilogram of body weight per day)
Study: 26242122
Drug: Integrative medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative medicine treatment group (anti‐virus Western medicine plus CQG)
Study: 26242122
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine treatment group (treated with anti‐virus Western medicine)
Study: 16878257
Drug: Genotyping-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotyping-based treatment switch (group 1)
Study: 1324645
Drug: Amoxicillin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (500 mg three times daily for 5 days)
Study: 6370581
Drug: 4% aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% aqueous sodium lauryl sulfate (SLS) solution applied for 24 hours
Study: 21144223
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate nasal spray (FFNS), 110 micrograms, once daily for 4 weeks
Study: 19428097
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate nasal spray (FFNS)
Study: 7978086
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Treatment (CB) for ASPs
Study: 7978086
Drug: Relationship Enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relationship Enhancement Treatment for ASPs
Study: 7767
Drug: Formula 2
Normalized name: Formula 21
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula 2 (3.0 gm of protein per 100 ml, 60:40)
Study: 7767
Drug: Formula 1
Normalized name: Abena Man Formula 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula 1 (1.5 gm of protein per 100 ml, 60:40)
Study: 7767
Drug: Formula 3
Normalized name: Formula 3200
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Formula 3 (1.5 gm of protein per 100 ml, 18:82)
Study: 19417866
Drug: 30% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30% carbamide peroxide with 5% potassium nitrate (treatment A)
Study: 19417866
Drug: 30% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30% carbamide peroxide without potassium nitrate (treatment B)
Study: 11579707
Drug: Methotrexate (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (starting at 7.5 mg/week, max 20 mg/week)
Study: 26166166
Drug: Octreotide long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide long-acting release (OctLAR) 40 mg monthly
Study: 23214253
Drug: Control (antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (antibiotics plus hemostatics with usual wound care)
Study: 12271412
Drug: Potassium iodide
Normalized name: Potassium Iodide
DrugBank: Potassium Iodide (DB06715)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Potassium iodide (KI) 100 mg per day starting 2 days before (131)I-lipiodol administration and continuing until 2 weeks after therapy; n=31
Study: 31840388
Drug: Prophylactic oral
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic oral antiviral use pre- and post-treatment
Study: 22609501
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion at 25 microgram/kg/min
Study: 22609501
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion at 50 microgram/kg/min
Study: 22609501
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion at 75 microgram/kg/min
Study: 16710252
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with enalapril (10 mg)
Study: 16968506
Drug: Nurse-administered propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-administered propofol sedation with BIS visible (Phase 1)
Study: 16968506
Drug: Nurse-administered propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-administered propofol sedation with BIS visible (Phase 2)
Study: 25098596
Drug: Intrapulmonary percussive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapulmonary percussive ventilation (IPV) combined with chest physical therapy (CPT)
Study: 25098596
Drug: Traditional standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional standard chest physical therapy (CPT)
Study: 22321885
Drug: Palonosetron (drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron (drug A)
Study: 22333250
Drug: Calcineurin inhibitors
Normalized name: Calcineurin inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcineurin inhibitors (CNI)
Study: 8233296
Drug: Hyperfractionated accelerated
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperfractionated accelerated radiotherapy (2 x 1.6 Gy/day, 5 days per week: total dose, 64‐67.2 Gy) and simultaneous intravenous carboplatin (60 mg/m2, days 1‐5 and 29‐33).
Study: 25123600
Drug: Zonisamide 200
Normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Zonisamide 200 mg
Study: 25123600
Drug: Zonisamide 400
Normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Zonisamide 400 mg
Study: 20116047
Drug: Deep brain
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep brain stimulation (DBS) of the ventral capsule/ventral striatum
Study: 15864805
Drug: Intravascular radiation
Normalized name: acellular tissue engineered vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravascular radiation therapy (IRT) with iridium (Ir)-192 (n = 60)
Study: 6510013
Drug: Hydrochlorothiazide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (25 mg), amiloride (2.5 mg), and timolol (10 mg) taken before food
Study: 27191689
Drug: Bortezomib-PLD (bortezomib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib-PLD (bortezomib plus pegylated liposomal doxorubicin 30 mg/m² intravenously on day 4)
Study: 27191689
Drug: Bortezomib alone
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib alone (1.3 mg/m² intravenously on days 1, 4, 8, and 11 of every 21-day cycle)
Study: 1971516
Drug: Cetirizine 10
Normalized name: cetirizine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 10 mg once daily
Study: 26420821
Drug: Relaxation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation therapy (10 sessions)
Study: 15872029
Drug: bezafibrate retard
Normalized name: bezafibrate
DrugBank: Bezafibrate (DB01393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bezafibrate retard 400 mg once daily
Study: 15872029
Drug: triglycerides (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: triglycerides (50 mg/dL increment)
Study: 12079015
Drug: Intra-articular bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular bupivacaine 150 mg + morphine 4 mg
Study: 353682
Drug: Methylprednisolone sodium
Normalized name: methylPREDNISolone sodium phosphate
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone sodium succinate intravenously, 30 mg/sq m every six hours (conventional dose)
Study: 7168176
Drug: 50 mcg
Normalized name: D3, 50 mcg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mcg sulprostone administered intramurally into the cervix
Study: 7168176
Drug: 4 injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 injections of 250 micrograms sulprostone administered intragluteally at 4 hour intervals
Study: 20332140
Drug: Triplet chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triplet chemotherapy
Study: 8876342
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (4 . day‐1 x 5 g Cr.H2O + 2 g sucrose)
Study: 8876342
Drug: Placebo (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4 . day‐1 x 5 g Polycose + 2 g sucrose)
Study: 6654627
Drug: Atropine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (3 X 0.66 mg)
Study: 6654627
Drug: Atropine +
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine + Cyproheptadine (3 X 4 mg)
Study: 6654627
Drug: Carbenoxolone (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbenoxolone (3 X 100-3 X 50 mg)
Study: 26944891
Drug: Intramuscular injections
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injections of 2 units of botulinum toxin type A (BTX‐A)
Study: 26944891
Drug: Intramuscular injections
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injections of 4 units of botulinum toxin type A (BTX‐A)
Study: 25252807
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy intervention (CBTi) for fear of falling
Study: 22698066
Drug: Sugammadex 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 4 mg.kg(‐1) administered at 1‐2 post‐tetanic count (deep blockade)
Study: 22698066
Drug: Neostigmine 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 50 μg.kg(‐1) plus atropine 10 μg.kg(‐1) administered at the re‐appearance of the second twitch of a train‐of‐four stimulation (moderate blockade)
Study: 25048848
Drug: Topical 5%
Normalized name: urea topical 5% topical lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5% 250 mg imiquimod ointment followed by intradermal TIV
Study: 25048848
Drug: Topical aqueous-cream
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical aqueous-cream followed by intramuscular TIV
Study: 18471387
Drug: 100 mL
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL of contrast agent
Study: 18471387
Drug: 80 mL
Normalized name: urinary bag 480 mL MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mL of contrast agent
Study: 18471387
Drug: 60 mL
Normalized name: Disposable Nurser 60 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mL of contrast agent
Study: 18471387
Drug: 40 mL
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mL of physiological serum at a rate of 4 ml/s
Study: 12915640
Drug: 3 IU
Normalized name: Vitamin A/Vitamin D 1250 IU-133 IU Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 IU GH/m(2).d (approximately 0.033 mg/kg.d)
Study: 12915640
Drug: 6 IU
Normalized name: Coenzyme Q10/Vitamin E 30 MG-6 IU Oral Capsule, Liquid Filled
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 IU GH/m(2).d (approximately 0.067 mg/kg.d)
Study: 10555031
Drug: Serum COMP
Normalized name: TITANIUM DIOXIDE 4.9 g in 100 g / OCTINOXATE 2 g in 100 g TOPICAL POWDER [ISAKNOX AGELESS SERUM COMPACT 23]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum COMP levels in OA group (1,208.57 ± 487.47 ng/ml)
Study: 10555031
Drug: Serum COMP
Normalized name: TITANIUM DIOXIDE 4.9 g in 100 g / OCTINOXATE 2 g in 100 g TOPICAL POWDER [ISAKNOX AGELESS SERUM COMPACT 23]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum COMP levels in age > or = 65 group (1,302.1 ± 496.7 ng/ml)
Study: 1750602
Drug: Single-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose oral famotidine
Study: 1750602
Drug: Double-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-dose oral ranitidine
Study: 27913991
Drug: Preservative-free dorzolamide/timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preservative-free dorzolamide/timolol fixed combination (triple PF regimen)
Study: 7712677
Drug: Lidocaine infusion
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine infusion (8-hour initial infusion followed by 40-hour infusion)
Study: 7712677
Drug: Placebo (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (after 8-hour lidocaine infusion)
Study: 2565329
Drug: NAD (nadolol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAD (nadolol, 80 mg/day)
Study: 2565329
Drug: AT (atenolol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: AT (atenolol, 100 mg/day)
Study: 31757033
Drug: High-dose GSPE
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose GSPE (400 mg/day)
Study: 31757033
Drug: Low-dose GSPE
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose GSPE (200 mg/day)
Study: 21875472
Drug: Intravesical gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical gemcitabine 2000 mg
Study: 21875472
Drug: Original intravesical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original intravesical chemotherapy
Study: 16961291
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) 300 mg three times daily
Study: 12965314
Drug: Preop‐TEA (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preop‐TEA (8 mL of 0.25% bupivacaine plus fentanyl 50 microg in 2 mL administered preoperatively)
Study: 12965314
Drug: Postop‐TEA (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postop‐TEA (no medication administered preoperatively and intraoperatively, postoperative analgesia maintained with patient‐controlled epidural analgesia with bupivacaine and fentanyl solution)
Study: 10852444
Drug: Hypoglycemic clamp
Normalized name: CLAMP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglycemic clamp of 2.9 +/‐ 0.1 mmol/L after euglycemia (5.1 +/‐ 0.1 mmol/L) on day 1
Study: 10852444
Drug: Antecedent hypoglycemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antecedent hypoglycemia of 3.9, 3.3, and 2.9 +/‐ 0.1 mmol/L
Study: 10852444
Drug: Identical day
Normalized name: MENTHOL 20 g in 100 mL TOPICAL EMULSION [DentiCalm]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical day 1 hypoglycemia of 3.9, 3.3, and 2.9 +/‐ 0.1 mmol/L
Study: 31303281
Drug: Lusutrombopag (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lusutrombopag (2 mg) in fed state
Study: 31303281
Drug: Lusutrombopag (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lusutrombopag (0.75 mg) in fasted state
Study: 27006014
Drug: Ultrasound-guided lateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided lateral femoral cutaneous nerve (LFCN) block with 8 ml of ropivacaine, 7.5 mg/ml (Group Ropivacaine)
Study: 27006014
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with 8 ml of saline (Group Placebo)
Study: 24631129
Drug: ITCA 650
Approvals — FDA: no, EMA: no, PMDA: no
Description: ITCA 650 (20, 40, 60 or 80 μg/day)
Study: 24631129
Drug: ITCA 650
Approvals — FDA: no, EMA: no, PMDA: no
Description: ITCA 650 (80 μg/day)
Study: 12017402
Drug: Montelukast 10
Normalized name: montelukast 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 10 mg once daily at bedtime
Study: 1978496
Drug: Remoxipride (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remoxipride (low dose: 30-90 mg daily)
Study: 1978496
Drug: Haloperidol (15-45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (15-45 mg daily)
Study: 1978496
Drug: Remoxipride (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remoxipride (all doses)
Study: 580070
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (CVP: cyclophosphamide, vincristine, and prednisone)
Study: 580070
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (CVP)
Study: 580070
Drug: Successive single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Successive single agent chemotherapy (C-V-P)
Study: 9231814
Drug: Active drug
Normalized name: Capillary active drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active drug controls
Study: 9231814
Drug: Nifedipine in
Normalized name: nifedipine Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine in combination with another drug
Study: 9231814
Drug: Nifedipine monotherapy
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine monotherapy vs combined therapy
Study: 8215633
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) 0.14 mg/kg/day
Study: 26980460
Drug: Bitopertin 5
Normalized name: Bitopertin
DrugBank: Bitopertin (DB12426)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bitopertin 5 mg/day
Study: 25651610
Drug: 500 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 g/day banana for 12 weeks
Study: 7851580
Drug: Low-dose estrogen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose estrogen oral contraceptives (OC)
Study: 1778190
Drug: Intermittent therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent therapy with transdermal glyceryl trinitrate
Study: 1778190
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo transdermal patches
Study: 6247910
Drug: Prophylactic granulocyte
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic granulocyte transfusions and oral nonabsorbable antibiotics (group 1)
Study: 6247910
Drug: Oral nonabsorbable
Normalized name: COLLAGEN HEMOSTAT,ABSORBABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nonabsorbable antibiotics alone (group 2)
Study: 19118875
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone gel therapy for 3 months
Study: 17006963
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for moderate varicose veins
Study: 20415638
Drug: rhGH 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH 1.5 mg scqd + ART for 48 weeks (Arm A)
Study: 20415638
Drug: ART alone
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ART alone for 24 weeks then rhGH 3.0 mg scqd for 24 weeks (Arm B)
Study: 1330318
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg sumatriptan
Study: 1335361
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg sumatriptan
Study: 6367368
Drug: Adrenergic beta‐receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenergic beta‐receptor blockade with oxprenolol
Study: 30221438
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no dog-assisted therapy)
Study: 11451599
Drug: Sucralfate Cream
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucralfate Cream
Study: 3061311
Drug: Bambuterol 0.270
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bambuterol 0.270 mg/kg
Study: 21292895
Drug: Oral miltefosine
Normalized name: Miltefosine
DrugBank: Miltefosine (DB09031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral miltefosine (2.5 mg/kg/day for 28 days)
Study: 26928838
Drug: Oral Cholera
Normalized name: VIBRIO CHOLERAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Cholera Vaccine (OCV)
Study: 18415764
Drug: Three disease-modifying
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three disease-modifying anti-rheumatic drugs (DMARDs) and low-dose prednisolone (COMBI)
Study: 18415764
Drug: Single DMARD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single DMARD with or without low-dose prednisolone (SINGLE)
Study: 12028323
Drug: Frovatriptan doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frovatriptan doses of 2.5 to 40 mg
Study: 12028323
Drug: Frovatriptan doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frovatriptan doses of 0.5 mg and 1 mg